CARNA BIOSCIENCES

News Release

March 12, 2024
Carna Biosciences, Inc.

Carna Biosciences to present new preclinical data on monzosertib at AACR Annual Meeting

Carna Biosciences, a clinical-stage biopharmaceutical company focusing on the discovery and development of innovative therapies to treat serious unmet medical needs, announces that preclinical data for monzosertib (AS-0141) will be presented at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 5-10 in San Diego, California.

Mozosertib is an investigational potent, selective, and orally bioavailable small molecule inhibitor of CDC7 kinase, currently in a Phase 1 clinical study in Japan in patients with advanced, metastatic, relapsed or refractory malignancies. The poster will be featuring synergistic effects of monzosertib in combination with current standard of care agents in preclinical models of acute myeloid leukemia (AML) *in vitro* and *in vivo*.

Presentation Details

Abstract Number: 5714

Poster title:	Synergistic effect of the CDC7 inhibitor, monzosertib (AS-0141) with current therapies in AML models
Session title:	PO.MCB01.01 - Pharmacologic Targeting of Cell Cycle Proteins
Session date and time:	Tuesday Apr 9, 2024 1:30 PM - 5:00 PM PT
Presenter:	H. Endo, H. Furuichi, A. Arimura, Y. Nishioka, M. Sawa

The abstract is available at: https://www.abstractsonline.com/pp8/#!/20272/presentation/1632

About monzosertib (AS-0141)

CDC7 (cell division cycle 7) is a serine-threonine kinase that plays a critical role in DNA synthesis and is required for the activation of DNA replication origins throughout the S phase of the cell cycle. Inhibition of CDC7 in cancer causes lethal S phase or M phase progression, whereas normal cells survive, most likely through induction of cell cycle arrest at the DNA replication checkpoint. It has been reported in the literature that CDC7 is overexpressed in many types of cancers, therefore CDC7 is an attractive target for cancer drug development. Carna has successfully identified a selective and potent CDC7 inhibitor, monzosertib, with a unique mechanistic slow off-rate.

Contact:
Corporate Planning
Carna Biosciences, Inc.
TEL: +81-78-302-7075
https://www.carnabio.com/english/